Ellipses Pharma Ltd.
Records under this name other than the patents Ellipses Pharma Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.
Showing 1 to 8 of 8 · Back to Ellipses Pharma Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,956,296 | Compounds containing a vascular disrupting agent Lapsed on the fee record Ended May 1, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 1, 2026 | From the USPTO record |
| US 9,937,267 | Methods of treating cancer using compounds containing a vascular disrupting agent Lapsed on the fee record Ended Apr 10, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 10, 2026 | From the USPTO record |
| US 8,691,751 | Compounds containing a vascular disrupting agent Lapsed on the fee record Ended Apr 8, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 8, 2026 | From the USPTO record |
| US 10,912,839 | Methods of treating cancer using compounds containing a vascular disrupting agent Lapsed on the fee record Ended Feb 9, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 9, 2025 | From the USPTO record |
| US 9,358,303 | Compounds containing a vascular disrupting agent Lapsed on the fee record Ended Jun 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jun 7, 2024 | From the USPTO record |
| US 10,556,014 | Compounds containing a vascular disrupting agent Lapsed on the fee record Ended Feb 11, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 11, 2024 | From the USPTO record |
| US 10,201,622 | Tumour-targeted theranostic Lapsed on the fee record Ended Feb 12, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 12, 2023 | From the USPTO record |
| US 8,927,486 | Compounds Lapsed on the fee record Ended Jan 6, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jan 6, 2023 | From the USPTO record |